KANEKA CORPORATION forecasts consolidated net profit of ¥32.0 billion for the fiscal year ending March 2027, up 3% from the previous fiscal year, and has revised revenue and operating profit upward to ¥890.0 billion and ¥48.0 billion, respectively. It expects growth in medical-device sales and reduced coenzyme Q10.
KANEKA CORPORATION announced on the 11th that consolidated net profit for the fiscal year ending March 2027 is expected to rise 3% year on year to ¥32.0 billion. Revenue has been revised upward to ¥890.0 billion, up 10%, and operating profit to ¥48.0 billion, up 46%, both above the previous forecasts. The company said the increases are expected to be supported by growth in medical-device sales and stronger promotion of reduced coenzyme Q10.
The consolidated results for April–September 2026, also announced that day, showed revenue of ¥446.9 billion, up 12% year on year, and net profit of ¥14.6 billion, up 33%. Both revenue and operating profit reached record highs. The results were supported by the increasing penetration of price pass-through and expanded sales of blood purification devices, catheters and reduced coenzyme Q10.
The upward revision to the outlook appears to reflect expanded sales in the medical-device business and growing demand for reduced coenzyme Q10. KANEKA CORPORATION said it aims to continue growing by strengthening promotion of medical devices and expanding its cosmetics and supplements businesses in response to changes in the market environment.
The strong results for April–September 2026 were largely attributable to expanded sales of blood purification devices and catheters and the increasing penetration of price pass-through. The company indicated that sales of these product groups may continue to contribute to results.